Maze Therapeutics

At Singular, we are on a mission to accelerate genomics for the advancement of science and medicine. Laure joined Singular Genomics with more than 18 years of experience in scientific customer support for the life science industry. Fong cofounded several companies including FWB LLC (acquired by Streamlogic), Techbargains.com LLC (acquired by Exponential), and Keyhole Therapeutics. Elaine Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis and treatment. Prior to that, Jason served as the CFO of Foundation Medicine, a transformative company in oncology molecular profiling. Kamdar is a Managing Partner at Domain Associates, a venture capital fund focused on healthcare company creation. Kim is the author of ten papers as well as the inventor on seven patents. Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences.

We are a start-up originally spun out of Dr. Dhivya is a passionate Entrepreneur with 15+ years experience in defining winning strategies and building high performance teams. Vergara has 14+ years of experience in experimental and computational biology. Shellard has a PhD and 12+ years of experience in cell biology and live imaging. Brian brings a track record of leading teams to deliver transformative results for clients across the healthcare sector at McKinsey and Company with particular focus on strategy / corporate finance, go-to-market, and M&A. Laghrissi is the CEO of DalCor Pharmaceuticals and has more than 20 years of pharmaceutical industry leadership experience, including roles at AstraZeneca, Roche, HBA and WPIC. Kupfer is the ex-Head of the DSM-5 plan committee, and has expert knowledge of the current principal manual for psychiatric & neurocognitive diagnosis, as recommended by the American Psychiatric Association. Linder is the CEO at Calciscon AG, biomedical consultant, entrepreneur & senior biotech executive with track record of success for biomedical devices.

Dannielle served as the chief executive officer of Rubius Therapeutics, Inc., from November 2022 until its dissolution in March 2023. Sonia brings more than 20 years of experience managing quality and operations for small and large molecule companies, spanning from clinical development to commercial product lifecycle management. Before joining Generation Bio, Sonia served as the senior director, GxP Quality at Ironwood Pharmaceuticals. Ron served as the president and chief executive officer of Albireo Pharma, Inc., from July 2015 and a member of its board of directors from November 2016, both until its acquisition by Ipsen Biopharmaceuticals, Inc. While at BMS, Ron played a leadership role in several product successes, including Abilify®, Avapro®, Atripla®, Eliquis®, Orencia®, Pravachol®, Plavix®, Reyataz®, Sustiva®, Sprycel®, and Yervoy®. Before coming to Generation Bio, Tracy served as the senior director, research, at Alnylam Pharmaceuticals. While at the NIH, Rob's laboratory invented and developed a scalable recombinant AAV (rAAV) production process in Sf9 cells that was licensed by several companies and used to produce Glybera™, the first rAAV product granted regulatory agency approval for sale. The research at the NIH resulted in the discovery of an AAV replicative product that has been described as closed-ended linear duplex DNA.

Working together to deliver cell and gene therapies for people impacted by serious diseases. Gene therapy is the use of DNA as a potential therapy to treat a disease. Seshadri has more than 20 years of experience including academia and various senior and executive leadership roles in the life sciences industry overseeing product development, regulatory submissions, and commercialization for novel therapies including personalized, autologous cell and gene therapies. Krzysztof Palczewski, involved studying both the biochemical basis of retinal development as well as the pathophysiology of animal models of blinding diseases. Vazzano secured multiple equity financings for Avenue and served in a leadership role for signing a complex, two-stage acquisition of Avenue with future contingent value rights. Vazzano has a Bachelor of Science degree in Accounting from Lehigh University and is a Certified Public Accountant in the State of New Jersey. Denny has over 20 years of experience in Chemistry Manufacturing and Controls (CMC) and regulatory affairs in the registration of gene therapies and mRNA products including AMONDYS 45 (casimersen) and AAV-based gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). Gin has served as the Head of Investor Relations at four public companies and brings more than 25 years of investor relations, communications, and capital markets experience with small- and mid-cap biotechnology and specialty pharmaceutical companies developing novel treatments for orphan diseases and areas of high unmet medical need.

We are leveraging our multi-disciplinary wetlab capabilities and partnership with Versant Ventures. Inception Therapeutics is a multi-disciplinary discovery engine founded in 2011 with Versant Ventures to build and launch transformative new biotechnology companies. Prior to the BD role, Richard served as an Executive Director, leading a research group at the Genomics Institute of the Novartis Research Foundation, that focused on infectious disease and immunology and contributed to multiple pre-clinical and clinical development programs. Don brings expertise in all aspects of drug discovery from early lead identification through clinical candidate selection. Cravatt is a Professor in the Department of Chemistry and Gilula Chair Chemical Biology at The Scripps Research Institute. Cravatt is a co-founder and scientific advisor of Activx Biosciences, Abide Therapeutics and Vividion Therapeutics. Tom Daniel has more than 20 years of experience leading and building research and development organizations and leading investments in new companies at the forefront of innovative applications of science and healthcare. Carolyn Bertozzi is the Baker Family Director of Stanford ChEM-H and the Anne T.

Erin has more than 20 years HR leadership experience across biotech, medical device, manufacturing and entertainment industries. Jean is a General Partner of Lightstone Ventures. Mark Iwicki has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas for several high-performance companies. Mark is the Chairman and CEO of Kala Pharmaceuticals and previously was CEO of Civitas Therapeutics which was sold to Acorda Therapeutics in 2014. Katharine Knobil has more than 20 years of experience in the pharmaceutical industry including global clinical research, medical affairs, and patient safety across both big pharma and smaller biotechnology companies. Vlasuk is a scientifically trained executive with nearly 40 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies. George is the author of more than 100 peer-reviewed scientific publications, book chapters and reviews, and 38 issued U.S.